Former CDC Immunization Program Director Joins Board of Sabin Vaccine Institute

NEW CANAAN, CT—The Board of Trustees of the Albert B. Sabin Vaccine Institute announced the election of their newest board member, Walter Orenstein, MD. Recently recruited as Professor of Medicine and Pediatrics at Emory University School of Medicine, Dr. Orenstein’s posts at Emory will include director of the Program for Vaccine Policy and Development and associate director of the Vaccine Center. Dr.

Sabin

Researchers to Meet on Cutting-edge Cancer Vaccine Development at 2004 Colloquium on Cancer Vaccines and Immunotherapy

NEW CANAAN, CT— Approximately forty of the world’s leading cancer vaccine researchers will meet this week at a scientific colloquium organized by the Albert B. Sabin Vaccine Institute. Convening in think-tank sessions, they will report on the latest developments in this promising field of therapy focused on stimulation of the body’s immune system to attack existing cancerous cells.

Sabin

Sabin Vaccine Institute a Sponsor of the 2nd Biodefense Vaccines, Therapeutics and Diagnostics Conference

The U.S. Government's commitment to rapidly develop biomedical countermeasures against bioterrorist threats has stimulated a tremendous boost to biodefense research, a big push to expand research resources and facilities, and a growing dedication to build a robust biodefense industry.

Sabin

Sabin Institute Scientist Receives Tropical Medicine Medal

PHILADELPHIA, PA, December 3, 2003—Hartford, Connecticut native Peter J. Hotez, MD, PhD, FAAP claimed the 2003 Bailey K. Ashford Medal here today at the centenary meeting of the American Society of Tropical Medicine and Hygiene. Hotez is chairman of Microbiology and Tropical Medicine, The George Washington University, and senior fellow of the Albert Sabin Vaccine Institute, headquartered in New Canaan, Connecticut.

Sabin

Sabin Vaccine Institute Concludes 2nd Meeting of the Cancer Vaccine Consortium

NEW CANAAN, CT, November 4, 2003—The Sabin Vaccine Institute, a non-profit research and education organization based in New Canaan, today concluded the second meeting of the Cancer Vaccine Consortium (CVC). The three-day meeting was held in Bethesda, Maryland and drew attendees from the United States, Canada and Europe. The purpose of the CVC is to enhance collaboration among companies undertaking research and development on cancer immunotherapies.

Sabin

Pages